Skip to main content

Table 1 Baseline characteristics between never-users and ever-users of rosiglitazone

From: Rosiglitazone may reduce non-melanoma skin cancer risk in Taiwanese

Variables

Never-users

Ever-users

P

 

n

%

n

%

 

n = 886418

783321

 

103097

  

Age (years)

     

 <40

33874

4.32

3269

3.17

<0.0001

 40-49

102887

13.13

11623

11.27

 

 50-59

199819

25.51

27204

26.39

 

 60-69

200241

25.56

29608

28.72

 

 ≥70

246500

31.47

31393

30.45

 

Sex (men)

399333

50.98

49282

47.80

<0.0001

Diabetes duration (years)

     

 <1

70381

8.98

1434

1.39

<0.0001

 1-3

133250

17.01

7184

6.97

 

 3-5

123610

15.78

11094

10.76

 

 ≥5

456080

58.22

83385

80.88

 

Hypertension

443728

56.65

77740

75.40

<0.0001

Chronic obstructive pulmonary disease

114018

14.56

24177

23.45

<0.0001

Cerebrovascular disease

116947

14.93

25453

24.69

<0.0001

Nephropathy

93744

11.97

23717

23.00

<0.0001

Ischemic heart disease

174225

22.24

40511

39.29

<0.0001

Peripheral arterial disease

89324

11.40

24510

23.77

<0.0001

Eye disease

63803

8.15

21179

20.54

<0.0001

Obesity

11423

1.46

1961

1.90

<0.0001

Dyslipidemia

371714

47.45

69015

66.94

<0.0001

Other cancer prior to baseline

93619

11.95

13058

12.67

<0.0001

Sulfonylurea

577003

73.66

99140

96.16

<0.0001

Metformin

512063

65.37

96850

93.94

<0.0001

Acarbose

80640

10.29

38971

37.80

<0.0001

Insulin

102359

13.07

39119

37.94

<0.0001